Format

Send to

Choose Destination
Clin Pharmacol Ther. 2017 Nov;102(5):786-795. doi: 10.1002/cpt.695. Epub 2017 Jun 5.

Building Capability for Clinical Pharmacology Research in Sub-Saharan Africa.

Author information

1
Novartis Pharma and Novartis Institutes for Biomedical Research, Basel, Switzerland and Cambridge, Massachusetts, USA.
2
Kenya Medical Research Institute (KEMRI)/Strathmore University (SU), Nairobi, Kenya.
3
Kintampo Health Research Center, Kintampo, Ghana.
4
University of Cape Town, Cape Town, South Africa.
5
Ifakara Health Institute, Bagamoyo, Tanzania.
6
African Institute of Biomedical Science & Technology, Harare, Zimbabwe.
7
Addis Ababa University/Regional Bioequivalence Center, Addis Ababa, Ethiopia.

Abstract

A strong scientific rationale exists for conducting clinical pharmacology studies in target populations because local factors such as genetics, environment, comorbidities, and diet can affect variability in drug responses. However, clinical pharmacology studies are not widely conducted in sub-Saharan Africa, in part due to limitations in technical expertise and infrastructure. Since 2012, a novel public-private partnership model involving research institutions and a pharmaceutical company has been applied to developing increased capability for clinical pharmacology research in multiple African countries.

PMID:
28378903
DOI:
10.1002/cpt.695
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center